AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06507657
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intake a placebo oral tablet~At visit 1, after randomization, participants will be provided with bottles containing enough study pills for 3 months duration at 1 tablet daily. Participants will start the study drug on the morning following Visit 1. At the 3 month follow up visit, participants will be provided with enough study pills to complete the remaining 6 months of the study.
Trial: NCT06544642
Drug: ASP5502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT06544642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT05877638
Drug: SILVADENE Cream 1% (silver sulfadiazine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SILVADENE Cream 1% (silver sulfadiazine) is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second- and third-degree burns.
Trial: NCT05971537
Drug: antibiotic lock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the intervention arm, in addition to the appropriate IP antibiotics, an antibiotic-lock will be prepared by the same antibiotics. We will follow the suggested data used in hemodialysis catheter for the concentration of different antibiotics to prepare the locking solution . Some commonly used antibiotics for the treatment of PD peritonitis with their suggested concentrations in the antibiotic-lock are quoted as below:~Cefazolin 10mg/mL Ceftazidime 10mg/mL Vancomycin 10mg/mL Gentamicin 5mg/mL Tienam 50mg/mL
Trial: NCT06198894
Drug: Systemic glucocorticoids
RxNorm normalized name: Glucocorticoids, Systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Groups were given oral methylprednisolone (32 mg/d on days 1-5; 16 mg/d on days 6-10; and 8 mg/d on days 11-20),
Trial: NCT06198894
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Groups were given systemic glucocorticoid placebo
Trial: NCT05187546
Drug: [18F]-PI2620
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 megabecquerel (MBq).
Trial: NCT05287724
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken twice daily for seven days
Trial: NCT05109078
Drug: [14C]- Rongliflozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive single dose of orally \[14C\]- Rongliflozin on Day 1
Trial: NCT06674525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous injection
Trial: NCT05612594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo once daily
Trial: NCT05582317
Drug: Biodentine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricalcium silicate, dicalcium silicate, calcium carbonate and oxide filler, iron oxide shade and zirconium oxide
Trial: NCT05582317
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
Trial: NCT05630677
Drug: AZD5055 solution for infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single dose intravenous infusion of AZD5055 as 20-minute infusion on Day 1 of the respective period in overnight fasted state.
Trial: NCT05630677
Drug: AZD5055 oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive single dose of AZD5055 oral suspension on Day 1 of the respective period in overnight fasted state.
Trial: NCT05630677
Drug: AZD5055 film-coated tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in overnight fasted state.
Trial: NCT05630677
Drug: AZD5055 film-coated tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive single oral dose of AZD5055 film-coated tablets on Day 1 of the respective period in fed state (either a high fat meal or low-fat meal calorie standard breakfast)
Trial: NCT05457400
Drug: Glucose Powder
RxNorm normalized name: Glucose powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g Glucose Powder dissolved in Water
Trial: NCT04713956
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Trial: NCT06082856
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction of general anesthesia by administration of sufentanil 0.25µg/Kg (maximum dose 20 µg) intravenously at anesthetic induction.
Trial: NCT05671913
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control arm
Trial: NCT05946798
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each
Trial: NCT05398510
Drug: SHR-2010 injection placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment for intravenously: 2 subjects for placebo. Treatment for subcutaneously: 2 subjects for placebo.
Trial: NCT06409637
Drug: FOLFOX4 regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX4 regimen: Oxaliplatin 85mg/m2 intravenous infusion over 2 hours on Day 1; Leucovorin 400mg/m2 intravenous infusion over 2 hours on Days 1-2; 5-Fluorouracil (5-FU) initially 400mg/m2 intravenous bolus followed by 2400mg/m2 continuous intravenous infusion over 46 hours. Each cycle lasts for 4 weeks, repeated every 4 weeks for a total of 6-8 cycles.
Trial: NCT06047262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive placebo.
Trial: NCT04799249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered IV over 30mins prior to chemotherapy on Day 1 and Day 8 of each 21-day cycle.
Trial: NCT05036317
Drug: Empagliflozin (Jardiance®;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each tablet contains the active substance of 10 mg empagliflozin as well as the adjuvant lactose-monohydrate and is taken orally once daily in the morning.
Trial: NCT04879966
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids was used as induction therapy in UC patients, the maintenance treatment was decided by the researcher
Trial: NCT05037032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for naltrexone
Trial: NCT05996133
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 mL epinephrine 1:400,000.
Trial: NCT05996133
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL normal saline
Trial: NCT00055432
Drug: Gemzar and Alimta
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04496674
Drug: CC-1 and Toczilizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adminsitration of CC-1 and Toczilizumab
Trial: NCT05351905
Drug: Placebo oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose will be 1 mL per day (contains no API) orally and gradually titrated to a maximum dose of 6 mL per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
Trial: NCT00005024
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005024
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05583240
Drug: Essences and Essential Oils
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will received Essential Oils through a nasal stick during 4 weeks.
Trial: NCT04703764
Drug: HSG4112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily, 14-day multiple oral administration
Trial: NCT04703764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily, 14-day multiple oral administration
Trial: NCT00378781
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin flush solution into CVC once daily.
Trial: NCT00378781
Drug: Minocycline-EDTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-EDTA flush solution into CVC once daily.
Trial: NCT04857892
Drug: GSK3640254
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3640254 will be administered via oral route.
Trial: NCT04857892
Drug: GSK3640254/DTG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3640254/DTG will be administered via oral route.
Trial: NCT04853199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each placebo capsule contains 150 mg of microcrystalline cellulose and 1.5 mg of magnesium stearate.
Trial: NCT04639024
Drug: ADCT-301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive ADCT-301 37.5 ug/kg infused day 1,8, and 15 of a q3week cycle. Patients will have up to 2 cycles to assess response and safety to therapy and if they are not progressing may continue for up to 6 cycles.
Trial: NCT06500234
Drug: Starch powder 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch powder 50 mg, oral, everyday
Trial: NCT05349097
Drug: SAD Placebo 30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will be randomized to receive a single oral dose of 30mg matching placebo
Trial: NCT05349097
Drug: SAD Placebo 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will be randomized to receive a single oral dose of 100mg matching placebo
Trial: NCT05349097
Drug: SAD Placebo 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will be randomized to receive a single oral dose of 200mg matching placebo
Trial: NCT05349097
Drug: SAD Placebo 400mg
RxNorm normalized name: placebo 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will be randomized to receive a single oral dose of 400mg matching placebo
Trial: NCT05349097
Drug: SAD Placebo 600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will be randomized to receive a single oral dose of 600mg matching placebo
Trial: NCT05349097
Drug: MAD IMG-004 50mg
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each participant will be randomized to receive daily oral dose of 50mg IMG-004 for 10 days
Trial: NCT05349097
Drug: MAD Placebo 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will be randomized to receive daily oral dose of 50mg matching placebo for 10 days
Trial: NCT05349097
Drug: MAD IMG-004 150mg
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each participant will be randomized to receive daily oral dose of 150mg IMG-004 for 10 days
Trial: NCT05349097
Drug: MAD Placebo 150mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will be randomized to receive daily oral dose of 150mg matching placebo for 10 days
Trial: NCT05349097
Drug: MAD IMG-004 300mg
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each participant will be randomized to receive daily oral dose of 300mg IMG-004 for 10 days
Trial: NCT05349097
Drug: MAD Placebo 300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will be randomized to receive daily oral dose of 300mg matching placebo for 10 days
Trial: NCT06090565
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Four 500 mg tablets will be administered orally to equal a 2 g dose.
Trial: NCT05536570
Drug: IncobotulinumtoxinA 100 UNT
RxNorm normalized name: incobotulinumtoxinA 100 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scalene injection
Trial: NCT05045872
Drug: domestic polysaccharide superparamagnetic iron oxide nanoparticle
RxNorm normalized name: iron oxide, nanoparticles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive contrast-enhanced renal magnetic resonance imaging with polysaccharide superparamagnetic iron oxide nanoparticle before renal angiography. Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.
Trial: NCT06027151
Drug: 1ml of 2% minocycline gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml of 2% minocycline gel sub gingivally at baseline visit
Trial: NCT06027151
Drug: 1ml of combination of 1% metronidazole gel and 2% minocycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml of the combination of 1% metronidazole gel and 2% minocycline subgingivally at baseline visit
Trial: NCT05132218
Drug: Ensatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prospective, exploratory, single-arm, multi-center, real-world research
Trial: NCT05822180
Drug: NANOS1 , argent colloïdal ,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, during 5 day
Trial: NCT05653037
Drug: RBD4059
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously Administered RBD4059 in Healthy Subjects.
Trial: NCT05653037
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously Administered Placebo in Healthys Subject.
Trial: NCT06169982
Drug: LY3209590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06009094
Drug: VC005 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VC005 Placebo group with Local topical application
Trial: NCT05236257
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care for the patients from the eligible external cohorts.
Trial: NCT06437639
Drug: Mexidol
RxNorm normalized name: Brexidol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurocytoprotector
Trial: NCT06185400
Drug: third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RC48+third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib) after EGFR-TKIs progression
Trial: NCT05401916
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received tramadol with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 500 mg tramadol in 100 mL of saline (5 mg/ml). The PCA device was adjusted as infusion: 2 ml/h, bolus: 2 ml, lockout period: 15 min.
Trial: NCT06214468
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collection of urine at different time intervals following ingestion of Tylenol only
Trial: NCT05987696
Drug: CD33/CLL1 dual CAR-NK cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK cell therapy
Trial: NCT05987696
Drug: super NK cell
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK cell therapy
Trial: NCT05390476
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500mg orally three times a day (continuously)
Trial: NCT00000768
Drug: Glutamic acid hydrochloride
RxNorm normalized name: Glutamic acid hydrochloride
DrugBank: Glutamic acid (DB00142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05038787
Drug: LY3473329
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05038787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04701190
Drug: Noradrenaline 0.1 microgram/kg/minute infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion dosage: 0.1 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.1 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus.
Trial: NCT04701190
Drug: Noradrenaline 0.05 microgram/kg/minute infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion dosage: 0.05 microgram/kg/minute After the end of the injection of heavy marcaine 0.5% to the subarachnoid space, the infusion of noradrenaline with a 0.05 microgram/kg/minute dosage will be started.~Noradrenaline will be continued until 5 minutes after delivery of fetus.
Trial: NCT05320536
Drug: Guilingji Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This medicine is capsule medicine, take method is oral.
Trial: NCT05320536
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This medicine is capsule medicine（Placebo）, take method is oral.
Trial: NCT04816890
Drug: M1 Pram P037
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of M1 Pram P037 in combination with a basal insulin.
Trial: NCT06243640
Drug: Buagafuran capsules, 15mg/ capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects took Buagafuran capsules; twice per day, respectively, after breakfast and dinner for 8 weeks;
Trial: NCT06243640
Drug: Buagafuran capsules mimic, 0mg/ capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects took Buagafuran capsules mimic. twice per day, respectively, after breakfast and dinner for 8 weeks;
Trial: NCT06362317
Drug: Gemox Chemotherapy（Gemox or GC）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy drugs: GC regimen is preferred, and if patients cannot tolerate it, GEMOX regimen is used.~Gemcitabine + oxaliplatin (GEMOX) regimen chemotherapy: every 21 days (3 weeks), 1000 mg/m2 of gemcitabine was administered intravenously for more than 30 min on the 1st and 8th day, and 100 mg/m2 of oxaliplatin was administered intravenously for 2h on the 1st day Gemcitabine + cisplatin (GC) regimen chemotherapy: 1250 mg/m2 was administered intravenously for 30 min on day 1 and day 8, respectively, and 100 mg/m2 was administered intravenously for 2 hours after gemcitabine treatment on day 1.
Trial: NCT05818306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04569760
Drug: 50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cannabinoid oil preparation dosed in 1ml increments
Trial: NCT04569760
Drug: Placebo Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral MCT Oil Preparation - No cannabinoids- titrated as tolerated up to a maximum of 8mls twice daily (equivalent to 200 mg- 800 mg total dose of the active product)
Trial: NCT05727735
Drug: Da Vinci Vessel Sealer Extend Energy Device with SureForm Stapling
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Vessel Sealer Extend Energy Device is integrated with the da Vinci system and uses bipolar energy technology to facilitate tissue dissection and vessel sealing.
Trial: NCT06066606
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are administered placebo
Trial: NCT05549297
Drug: Investigators Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigators choice of therapy
Trial: NCT06322017
Drug: Conventional care by antiarrhythmic drugs (flecainide, sotalol, amiodarone) or bradycardic drugs (all betablocker or calcium channel blocker therapy, digoxin)
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventricular rate control is carried out using negative chronotropic agents (e.g. beta-blockers, calcium channel blockers, digitalis, etc.) according to current recommendations. If this fails, ablation of the atrioventricular junction with placement of a permanent pacemaker can be carried out according to current recommendations. As part of this research, the choice of bradycardic drugs and interventions will be left to the discretion of the investigator according to the center's practices and current recommendations.~Rhythm control aims to reduce AF by cardioversion (if it persists) to restore sinus rhythm and subsequently maintain it by introducing anti-arrhythmic treatment. Several antiarrhythmic drugs (flecainide, sotalol or amiodarone) can be used in this setting. As part of this research, the choice of antiarrhythmic drugs will be left to the discretion of the investigator according to the center's practices and current recommendations.
Trial: NCT04696250
Drug: Antineoplastic and Immunomodulating Agents
RxNorm normalized name: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
Trial: NCT04478305
Drug: Duavive 0.45Mg-20Mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duavee, marketed as Duavive in Canada.
Trial: NCT04814121
Drug: Suxiao Jiuxin Pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).
Trial: NCT04814121
Drug: The placebo of Suxiao Jiuxin Pills
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.